IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Sector
Healthcare
Filed
Jul 17, 2026
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.
With each of our programs, we combine a deep understanding of disease and protein dynamics with our structure-based rational drug design expertise to identify the specific structural liabilities that limit existing therapies or approaches, and then design novel chemical scaffolds to directly address these limitations.
Our most advanced product candidate, BH-30643, is an OMNI-EGFR inhibitor being evaluated in SOLARA, a global Phase 1/2 clinical trial in patients with EGFR-mutant NSCLC.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 17, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 11, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Apr 24, 2026 | [Cover] Draft Registration Statement |
| D | Dec 10, 2025 | Notice of Exempt Offering of Securities |
| D | Jan 2, 2024 | Notice of Exempt Offering of Securities |
| D | Mar 1, 2021 | Notice of Exempt Offering of Securities |
| D | Jan 11, 2021 | Notice of Exempt Offering of Securities |
Contact and headquarters details
Key executives and officers
J. Jean Cui, Ph.D.
President, Chief Executive Officer, Director
Y. Peter Li, Ph.D., MBA
Executive Chairman
Jason Keyes, MBA
Chief Financial Officer, Executive Vice President
Vincent Liptak, J.D., Ph.D., MBA
General Counsel, Executive Vice President
Geoff Oxnard, M.D.
Chief Medical Officer, Executive Vice President
Sundeep Agrawal, M.D.
Director
Bihua Chen, MBA
Director
Carl L. Gordon, Ph.D., CFA
Director
Sheila Gujrathi, M.D.
Director
John Schmid, MBA
Director